表紙
市場調查報告書

癌症生物標誌物市場趨勢分析/競爭性市場佔有率/預測(2016-2026):類型(蛋白質生物標誌物/基因生物標誌物)/癌症類型/分析技術/應用/地區

Cancer Biomarkers Market Size, By Type (Protein Biomarker, Genetic Biomarker, and Others ), By Cancer Type, By Profiling Technology, By Application, and By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26

出版商 Blueweave Consulting & Research Private Limited 商品編碼 948274
出版日期 內容資訊 英文 180 Pages
商品交期: 最快1-2個工作天內
價格
癌症生物標誌物市場趨勢分析/競爭性市場佔有率/預測(2016-2026):類型(蛋白質生物標誌物/基因生物標誌物)/癌症類型/分析技術/應用/地區 Cancer Biomarkers Market Size, By Type (Protein Biomarker, Genetic Biomarker, and Others ), By Cancer Type, By Profiling Technology, By Application, and By Region ; Trend Analysis, Competitive Market Share & Forecast, 2016-26
出版日期: 2020年03月01日內容資訊: 英文 180 Pages
簡介

全球癌症生物標誌物市場預計到2019年將達到136.5億美元,到2026年將達到294.5億美元,在2020年至2026年的預測期內增長12.61%。預計將以CAGR的速度增長。對在癌症的多個階段使用生物標誌物的認識的提高正在推動市場增長。 在替代終點和藥物靶標開發中使用生物標誌物的迅速增加,參與癌症診斷研究的研究人員和學生的興趣不斷增加,並且在癌症研究中對生物標誌物的需求對於癌症生物標誌物市場的增長至關重要這是成功因素的一部分。

本報告調查了全球癌症生物標誌物市場,並提供了當前的市場趨勢,市場影響因素,按細分市場和地區進行的市場分析和預測以及主要公司的概況。

第1章調查框架

第2章調查方法

第3章執行摘要

第4章世界癌症生物標誌物分析

  • DROC分析
    • 生長因子
    • 抑制因子
    • 市場機會
    • 挑戰
  • 技術狀況
  • 監管框架
  • 公司市場佔有率分析
  • 波特的五力分析

第5章全球癌症生物標誌物市場概述

  • 市場估計/預測:金額基礎
    • 金額基礎
  • 市場佔有率和預測
    • 按類型
      • 蛋白質生物標誌物
      • 遺傳生物標記
      • 其他(細胞,病毒和碳水化合物生物標誌物)
    • 按癌症類型
      • 乳腺癌
      • 肺癌
      • 大腸癌
      • 前列腺癌
      • 甲狀腺癌
      • 膀胱癌
      • 腎臟癌
      • 其他
    • 分析技術
      • 組學技術
      • 成像技術
      • 免疫測定
      • 細胞遺傳學
      • 生物信息學
      • 其他
    • 按應用
      • 診斷
      • 藥物發現與開發
      • 預後
      • 風險評估
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區
      • 拉丁美洲
      • 中東/非洲

第六章北美癌症生物標誌物市場

  • 市場估計/預測:金額基礎
    • 金額基礎
  • 市場佔有率和預測
    • 按類型
    • 按癌症類型
    • 通過分析技術
    • 按應用
    • 按國家
      • 美國
      • 加拿大

第7章歐洲癌症生物標誌物市場

  • 市場估計/預測:金額基礎
    • 金額基礎
  • 市場佔有率和預測
    • 按類型
    • 按癌症類型
    • 通過分析技術
    • 按應用
    • 按國家
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲

第8章亞太癌症生物標誌物市場

  • 市場估計/預測:金額基礎
    • 金額基礎
  • 市場佔有率和預測
    • 按類型
    • 按癌症類型
    • 通過分析技術
    • 按應用
    • 按國家
      • 中國
      • 印度
      • 日本
      • 韓國
      • 亞太地區其他國家

第9章拉丁美洲癌症生物標誌物市場

  • 市場估計/預測:金額基礎
    • 金額基礎
  • 市場佔有率和預測
    • 按類型
    • 按癌症類型
    • 通過分析技術
    • 按應用
    • 按國家
      • 巴西
      • 墨西哥
      • 阿根廷
      • 其他拉丁美洲

第10章中東和非洲癌症生物標誌物市場

  • 市場估計/預測:金額基礎
    • 金額基礎
  • 市場佔有率和預測
    • 按類型
    • 按癌症類型
    • 通過分析技術
    • 按應用
    • 按國家
      • 沙特阿拉伯
      • 阿拉伯聯合酋長國
      • 南非
      • 其他中東/非洲

第11章公司簡介(公司簡介,財務矩陣,產品狀況,關鍵人物,關鍵競爭對手,聯繫地址和戰略展望)

  • Thermo Fisher Scientific
  • Bio-Rad Laboratories
  • Roche Diagnostics
  • Qiagen N.V.
  • Illumina
  • G.E. Healthcare
  • Agilent Technologies
  • Biomerieux SA
  • Merck & Co.
  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Danaher Corporation
  • Myriad Genetics
  • Sysmex Corporation
  • Hologic
  • Quest Diagnostics
  • 其他有前途的公司
目錄
Product Code: BWC19432

Title:
Cancer Biomarkers Market Size, By Type (Protein Biomarker, Genetic Biomarker, and Others (cell, viral, and carbohydrate biomarkers)), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Bladder Cancer, Kidney Cancer, and Others), By Profiling Technology (Omics Technologies, Imaging Technologies, Bioinformatics, Immunoassays, Cytogenetics, and Others), By Application (Diagnostics, Drug Discovery & Development, Prognostics, Risk Assessment, and Others), and By Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America); Trend Analysis, Competitive Market Share & Forecast, 2016-26.

According to BlueWeave Consulting, the Global Cancer Biomarkers market has reached USD 13.065 Billion in 2019 and estimated to reach USD 29.45 Billion in 2026, at a CAGR of 12.61% during the forecast period 2020-2026. Rising awareness about the usage of biomarkers at several stages of cancer pushing the market upward.

In addition, lack of physical activities, frequent sun & UV exposure, improper diet, and growing consumption of tobacco are some of the essential factors that have attributed to the escalating prevalence of cancer. Around 22% of cancer deaths are caused due to tobacco consumption and are regarded as the principal risk factor for cancer. Moreover, the growing demand for clinical diagnosis in cancer's early stages and geriatric population base further propels the usage rates of cancer biomarkers. Besides, few internal factors such as hormonal imbalance, genetic mutation, and metabolic mutation contribute towards the surge in cancer cases, which in turn boosts the demand for cancer biomarkers.

Surging utilization of the biomarkers in surrogate endpoints & drug targets developments, increasing interest among researchers & students regarding cancer diagnostic researchers, and need for the biomarkers in cancer research are few crucial success factors for the growth of the global cancer biomarkers market. Most epidemiological studies use biomarkers to examine various stages of human disease. It requires careful handling and storage of sensitive biological samples to obtain a great deal of information from small samples and reduce future research costs by using banked samples.

The genetic biomarker segment in Type is expected to grow at a very high CAGR during the forecast horizon

Based on Type, the genetic biomarker segment is forecasted to dominate during the forecast period, owing to the advancement of technologies to detect the mutation. Gene expression profiling (microarray), Next-generation sequencing (NGS), and polymerase chain reaction (PCR) are the essential technologies used for genetic biomarker discovery and diagnosis. Advancements in high-throughput technologies are the major factors driving the cancer biomarkers market.

Technological advancements

There have been significant technological developments over fields such as diagnostic imaging, immunoassays, omics technologies, and bioinformatics. Using advanced bioinformatics tools, developments in omics technology allow faster acquisition of proteomic, genomic, and metabolomics data and its alliance with clinical trial data. Over the past decade, the omics movement has growing biomarker applications in biomedical research. Additionally, developments in high-throughput genomic technologies facilitate the identification and analysis of key gene mutations and polymorphisms, thereby expanding the spectrum of available genomic biomarkers.

Increased incidence and prevalence of different types of cancer

There is a surge in the cases of cancer among the global population, which has boosted the demand for Cancer Biomarkers. As per the World Health Organization, it is anticipated to increase cancer cases over the next two decades further. Cancer is prevalent largely in lower and middle-income nations since they lack suitable healthcare infrastructure to combat the condition effectively. In addition, the cancer cases were higher in men than in women.

North America is expected to have the lion's share in the global Cancer Biomarkers market during the anticipated period.

By geography, the global Cancer Biomarkers Market segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to have the lion's share in the global cancer biomarkers market during the forecast period, owing to the adoption of advanced technologies, increasing the number of research studies for the development of novel biomarkers. The existence of a large number of pharmaceutical firms, rising funding and investments from public and private organizations, and the growing use of biomarkers in patient stratification and drug development method.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary Research Respondents
  • 2.5. Market Size Estimation
  • 2.6. Assumption for The Study
  • 2.7. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Cancer Biomarkers Insights

  • 4.1. DROC Analysis
    • 4.1.1. Growth Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. Technological Landscape
  • 4.3. Regulatory Framework
  • 4.4. Company Market Share Analysis, 2019
  • 4.5. Porter's Five forces analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Intensity of Rivalry

5. Global Cancer Biomarkers Market Overview

  • 5.1. Market Size & Forecast by Value, 2016-2026
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast 2016-2026
    • 5.2.1. By Type
      • 5.2.1.1. Protein Biomarker
      • 5.2.1.2. Genetic Biomarker
      • 5.2.1.3. Others (cell, viral, and carbohydrate biomarkers)
    • 5.2.2. By Cancer Type
      • 5.2.2.1. Breast Cancer
      • 5.2.2.2. Lung Cancer
      • 5.2.2.3. Colorectal Cancer
      • 5.2.2.4. Prostate Cancer
      • 5.2.2.5. Thyroid Cancer
      • 5.2.2.6. Bladder Cancer
      • 5.2.2.7. Kidney Cancer
      • 5.2.2.8. Others
    • 5.2.3. By Profiling Technology
      • 5.2.3.1. Omics Technologies
      • 5.2.3.2. Imaging Technologies
      • 5.2.3.3. Immunoassays
      • 5.2.3.4. Cytogenetics
      • 5.2.3.5. Bioinformatics
      • 5.2.3.6. Others
    • 5.2.4. By Application
      • 5.2.4.1. Diagnostics
      • 5.2.4.2. Drug Discovery & Development
      • 5.2.4.3. Prognostics
      • 5.2.4.4. Risk Assessment
      • 5.2.4.5. Others
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. Latin America
      • 5.2.5.5. Middle East & Africa

6. North America Cancer Biomarkers Market

  • 6.1. Market Size & Forecast by Value, 2016-2026
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast 2016-2026
    • 6.2.1. By Type
    • 6.2.2. By Cancer Type
    • 6.2.3. By Profiling Technology
    • 6.2.4. By Application
    • 6.2.5. By Country
      • 6.2.5.1. U.S
      • 6.2.5.2. Canada

7. Europe Cancer Biomarkers Market

  • 7.1. Market Size & Forecast by Value, 2016-2026
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast 2016-2026
    • 7.2.1. By Type
    • 7.2.2. By Cancer Type
    • 7.2.3. By Profiling Technology
    • 7.2.4. By Application
    • 7.2.5. By Country
      • 7.2.5.1. Germany
      • 7.2.5.2. U.K
      • 7.2.5.3. France
      • 7.2.5.4. Italy
      • 7.2.5.5. Rest of Europe

8. Asia Pacific Cancer Biomarkers Market

  • 8.1. Market Size & Forecast by Value, 2016-2026
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast 2016-2026
    • 8.2.1. By Type
    • 8.2.2. By Cancer Type
    • 8.2.3. By Profiling Technology
    • 8.2.4. By Application
    • 8.2.5. By Country
      • 8.2.5.1. China
      • 8.2.5.2. India
      • 8.2.5.3. Japan
      • 8.2.5.4. South Korea
      • 8.2.5.5. Rest of Asia Pacific

9. Latin America Cancer Biomarkers Market

  • 9.1. Market Size & Forecast by Value, 2016-2026
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast 2016-2026
    • 9.2.1. By Type
    • 9.2.2. By Cancer Type
    • 9.2.3. By Profiling Technology
    • 9.2.4. By Application
    • 9.2.5. By Country
      • 9.2.5.1. Brazil
      • 9.2.5.2. Mexico
      • 9.2.5.3. Argentina
      • 9.2.5.4. Rest of Latin America

10.Middle East & Africa Cancer Biomarkers Market

  • 10.1. Market Size & Forecast by Value, 2016-2026
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast 2016-2026
    • 10.2.1. By Type
    • 10.2.2. By Cancer Type
    • 10.2.3. By Profiling Technology
    • 10.2.4. By Application
    • 10.2.5. By Country
      • 10.2.5.1. Saudi Arabia
      • 10.2.5.2. UAE
      • 10.2.5.3. South Africa
      • 10.2.5.4. Rest of Middle East & Africa

11.Company Profile (Company Overview, Financial Matrix, Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 11.1. Thermo Fisher Scientific
  • 11.2. Bio-Rad Laboratories
  • 11.3. Roche Diagnostics
  • 11.4. Qiagen N.V.
  • 11.5. Illumina
  • 11.6. G.E. Healthcare
  • 11.7. Agilent Technologies
  • 11.8. Biomerieux SA
  • 11.9. Merck & Co.
  • 11.10. Abbott Laboratories
  • 11.11. Becton, Dickinson, and Company
  • 11.12. Danaher Corporation
  • 11.13. Myriad Genetics
  • 11.14. Sysmex Corporation
  • 11.15. Hologic
  • 11.16. Quest Diagnostics
  • 11.17. Other Prominent Players

List of Figures

Fig: Global Cancer Biomarkers Segmentation

Fig: Company Market Share Analysis, 2019

Fig: Global Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Global Cancer Biomarkers Market Share, By Region, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: North America Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: North America Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: North America Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Europe Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Europe Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Europe Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Asia-Pacific Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Latin America Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Latin America Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Latin America Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Size, By Value (USD Billion), 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Y-o-Y Growth, By Value, 2017-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Type, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Cancer Type, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Profiling Technology, By Value, 2016-2026

Fig: Middle-East & Africa Cancer Biomarkers Market Share, By Application, By Value, 2016-2026

Fig: Middle East & Africa Cancer Biomarkers Market Share, By Country, By Value, 2016-2026

List of Tables:

Table: Global Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Global Cancer Biomarkers Market Size, By Region, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: North America Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Europe Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Asia-Pacific Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Latin America Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Type, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Cancer Type, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Profiling Technology, By Value, 2016-2026

Table: Middle-East & Africa Cancer Biomarkers Market Size, By Application, By Value, 2016-2026

Table: Middle East & Africa Cancer Biomarkers Market Size, By Country, By Value, 2016-2026

Table: Thermo Fisher Scientific Financial Analysis

Table: Bio-Rad Laboratories Financial Analysis

Table: Roche Diagnostics Financial Analysis

Table: Qiagen N.V. Financial Analysis

Table: G.E. Healthcare Financial Analysis

Table: Agilent Technologies Financial Analysis

Table: Biomerieux SA Financial Analysis

Table: Merck & Co. Financial Analysis

Table: Abbott Laboratories Financial Analysis

Table: Danaher Corporation Financial Analysis